Who are Freeze-dried Human Protein C Concentrate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Talvey, Epkinly, Tzield, Leqvio, Trogarzo, Kybella.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/freeze-dried-human-protein-c-concentrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Freeze-dried Human Protein C Concentrate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Freeze-dried Human Protein C Concentrate (Freeze-dried Human Protein C Concentrate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Coagulation factor replacement. Area: Cardiovascular.

phase 2 Coagulation factor replacement Protein C Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Freeze-dried Human Protein C Concentrate (Freeze-dried Human Protein C Concentrate) — Takeda. Freeze-dried Human Protein C Concentrate works by replacing a clotting factor in the blood to prevent excessive clotting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Freeze-dried Human Protein C Concentrate TARGET	Freeze-dried Human Protein C Concentrate	Takeda	phase 2	Coagulation factor replacement	Protein C
Talvey	TALQUETAMAB	Janssen Biotech	marketed		T-cell surface glycoprotein CD3	2023-01-01
Epkinly	EPCORITAMAB	Genmab Us, Inc.	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	T-cell surface glycoprotein CD3	2023-01-01
Tzield	TEPLIZUMAB	Provention Bio Inc	marketed	CD3-directed Antibody [EPC]	T-cell surface glycoprotein CD3	2022-01-01
Leqvio	INCLISIRAN	Novartis	marketed		Proprotein convertase subtilisin/kexin type 9	2021-01-01
Trogarzo	IBALIZUMAB	Taimed Biologics Usa	marketed	CD4-directed Blocking Antibody [EPC]	T-cell surface glycoprotein CD4	2018-01-01
Kybella	DEOXYCHOLIC ACID	AbbVie	marketed	Cytolytic Agent [EPC]	G-protein coupled bile acid receptor 1	2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Coagulation factor replacement class)

Beijing Children's Hospital · 1 drug in this class
Bioverativ Therapeutics Inc. · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
National Center for Research Resources (NCRR) · 1 drug in this class
Takeda · 1 drug in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Freeze-dried Human Protein C Concentrate — Competitive Intelligence Brief. https://druglandscape.com/ci/freeze-dried-human-protein-c-concentrate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab